Shandong Boan Biotechnology Co., Ltd, a controlling subsidiary of China-based Luye Pharma Group (HKG: 2186), has entered into a strategic partnership with GenScript Biotech Corporation (HKG: 1548), a leading Contract Research Organization (CRO). The collaboration aims to develop and manufacture the small circular double-stranded DNA vector GenCircle dsDNA, which is devoid of resistance markers. This partnership is expected to enhance Boan’s capabilities in genetic engineering T cell technology platforms, “STEALTH CAR-T” and “ReceptorTAC,” for a high-end cell therapy layout. Financial details of the agreement were not disclosed.
Boan Biotechnology’s CAR-T Portfolio and Aspirations
Boan Biotechnology boasts an impressive portfolio of CAR-T therapies, including PR401 (Claudin 18.2 CAR-T) and P2-003 (Claudin 18.2 dual CAR-T) for gastric and pancreatic cancers, GPC3 CAR-T for solid tumors, universal CAR-T P2-002 for solid tumors, dual targeted CAR-T P2-004, and another universal CAR-T for the treatment of recurrent/refractory chronic lymphocytic leukemia and mantle cell lymphoma.
Cost-Effective Production Processes for CAR-T Therapies
Boan is committed to developing low-cost production processes based on its bispecific antibody (BsAb) platform, with the goal of reducing the cost of conventional CAR-T products by 60% to 80%. This initiative underscores Boan’s dedication to making advanced cell therapies more accessible and affordable.-Fineline Info & Tech
